TY - JOUR
T1 - Microfluidic cell stretching for highly effective gene delivery into hard-to-transfect primary cells
AU - Hur, Jeongsoo
AU - Park, Inae
AU - Lim, Kyung Min
AU - Doh, Junsang
AU - Cho, Ssang Goo
AU - Chung, Aram J.
N1 - Funding Information:
The authors acknowledge Mr. L. Hwang at COMSOL Inc. for technical support of the numerical simulations. The authors also thank Mr. H. Chae and Mr. G. Kang at Konkuk University; Prof. J. Park, Ms. Y. Bae, and Ms. G. Kang at Korea University; Dr. J. Lee at Toolgen Inc.; and Prof. I. Choi and Mr. H. An at the University of Seoul for their technical support and useful discussions. Provisional patents have been filed by the authors’ institution. This work is supported by the Samsung Research Funding and Incubation Center for Future Technology (grant no. SRFC-IT1802-03), the Korea University grant (K1916951), and the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2018R1D1A1B07045538).
Publisher Copyright:
© 2020 American Chemical Society.
PY - 2020/11/24
Y1 - 2020/11/24
N2 - Cell therapy and cellular engineering begin with internalizing synthetic biomolecules and functional nanomaterials into primary cells. Conventionally, electroporation, lipofection, or viral transduction has been used; however, these are limited by their cytotoxicity, low scalability, cost, and/or preparation complexity, especially in primary cells. Thus, a universal intracellular delivery method that outperforms the existing methods must be established. Here, we present a versatile intracellular delivery platform that leverages intrinsic inertial flow developed in a T-junction microchannel with a cavity. The elongational recirculating flows exerted in the channel substantially stretch the cells, creating discontinuities on cell membranes, thereby enabling highly effective internalization of nanomaterials, such as plasmid DNA (7.9 kbp), mRNA, siRNA, quantum dots, and large nanoparticles (300 nm), into different cell types, including hard-to-transfect primary stem and immune cells. We identified that the internalization mechanism of external cargos during the cell elongation-restoration process is achieved by both passive diffusion and convection-based rapid solution exchange across the cell membrane. Using fluidic cell mechanoporation, we demonstrated a transfection yield superior to that of other state-of-the-art microfluidic platforms as well as current benchtop techniques, including lipofectamine and electroporation. In summary, the intracellular delivery platform developed in the present study enables a high delivery efficiency (up to 98%), easy operation (single-step), low material cost (<$1), high scalability (1 × 106 cells/min), minimal cell perturbation (up to 90%), and cell type/cargo insensitive delivery, providing a practical and robust approach anticipated to critically impact cell-based research.
AB - Cell therapy and cellular engineering begin with internalizing synthetic biomolecules and functional nanomaterials into primary cells. Conventionally, electroporation, lipofection, or viral transduction has been used; however, these are limited by their cytotoxicity, low scalability, cost, and/or preparation complexity, especially in primary cells. Thus, a universal intracellular delivery method that outperforms the existing methods must be established. Here, we present a versatile intracellular delivery platform that leverages intrinsic inertial flow developed in a T-junction microchannel with a cavity. The elongational recirculating flows exerted in the channel substantially stretch the cells, creating discontinuities on cell membranes, thereby enabling highly effective internalization of nanomaterials, such as plasmid DNA (7.9 kbp), mRNA, siRNA, quantum dots, and large nanoparticles (300 nm), into different cell types, including hard-to-transfect primary stem and immune cells. We identified that the internalization mechanism of external cargos during the cell elongation-restoration process is achieved by both passive diffusion and convection-based rapid solution exchange across the cell membrane. Using fluidic cell mechanoporation, we demonstrated a transfection yield superior to that of other state-of-the-art microfluidic platforms as well as current benchtop techniques, including lipofectamine and electroporation. In summary, the intracellular delivery platform developed in the present study enables a high delivery efficiency (up to 98%), easy operation (single-step), low material cost (<$1), high scalability (1 × 106 cells/min), minimal cell perturbation (up to 90%), and cell type/cargo insensitive delivery, providing a practical and robust approach anticipated to critically impact cell-based research.
KW - Gene delivery
KW - Intracellular delivery
KW - Macromolecule delivery
KW - Microfluidics
KW - Nanoparticle delivery
KW - Primary cell transfection
UR - http://www.scopus.com/inward/record.url?scp=85094669049&partnerID=8YFLogxK
U2 - 10.1021/acsnano.0c05169
DO - 10.1021/acsnano.0c05169
M3 - Article
C2 - 33034446
AN - SCOPUS:85094669049
SN - 1936-0851
VL - 14
SP - 15094
EP - 15106
JO - ACS Nano
JF - ACS Nano
IS - 11
ER -